Thalomid thalidomide: Phase II data; marketed to treat cutaneous manifestations of erythema nodosum leprosum (ENL)

In a 169-patient Phase II trial, 30 percent of patients

Read the full 107 word article

How to gain access

Continue reading with a
two-week free trial.